Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2 (Q36081509)

https://api.crossref.org/works/10.1038/BJC.1995.354

12 August 2017

Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2 (English)

1 reference

5 July 2024

author name string

R. Gooding

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

5 July 2024

P. Riches

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

5 July 2024

G. Dadian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

5 July 2024

J. Moore

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

5 July 2024

M. Gore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

5 July 2024

language of work or name

English

0 references

publication date

1 August 1995

1 reference

full work available at URL

12 August 2017

https://europepmc.org/articles/pmc2033994?pdf=render

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

https://europepmc.org/articles/PMC2033994

5 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

https://europepmc.org/articles/PMC2033994?pdf=render

5 July 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7640231

http://www.nature.com/articles/bjc1995354.pdf

5 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/BJC.1995.354

http://www.nature.com/articles/bjc1995354

5 July 2024

1 reference

https://api.crossref.org/works/10.1038/BJC.1995.354

British Journal of Cancer

5 July 2024

published in

1 reference

12 August 2017

72

1 reference

12 August 2017

2

1 reference

12 August 2017

452-455

1 reference

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

The role of interleukin-2 in the biotherapy of cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

High serum-soluble interleukin-2 receptor is not associated with the immunosuppression in diffuse cutaneous leishmaniasis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033994

Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo

23 September 2018

1 reference

12 December 2020

A macrophage-derived factor that inhibits the production and action of interleukin 2

1 reference

12 December 2020

In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration

1 reference

12 December 2020

Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study

1 reference

12 December 2020

Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma

1 reference

12 December 2020

Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour

1 reference

12 December 2020

Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1995.354

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

1 reference